Free Trial

Grace Therapeutics (GRCE) Competitors

Grace Therapeutics logo
$3.08 -0.12 (-3.75%)
As of 07/25/2025 04:00 PM Eastern

GRCE vs. LFVN, IMAB, PBYI, BIOA, CCCC, NVCT, ACOG, MOLN, ENTA, and LYEL

Should you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Lifevantage (LFVN), I-Mab (IMAB), Puma Biotechnology (PBYI), BioAge Labs (BIOA), C4 Therapeutics (CCCC), Nuvectis Pharma (NVCT), Alpha Cognition (ACOG), Molecular Partners (MOLN), Enanta Pharmaceuticals (ENTA), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.

Grace Therapeutics vs. Its Competitors

Lifevantage (NASDAQ:LFVN) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Lifevantage has a net margin of 4.12% compared to Grace Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 34.67% beat Grace Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lifevantage4.12% 34.67% 15.24%
Grace Therapeutics N/A -19.45%-16.99%

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 20.7% of Lifevantage shares are owned by insiders. Comparatively, 13.5% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lifevantage presently has a consensus target price of $30.50, indicating a potential upside of 122.47%. Grace Therapeutics has a consensus target price of $12.00, indicating a potential upside of 289.61%. Given Grace Therapeutics' higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Lifevantage.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifevantage
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Grace Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lifevantage has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Lifevantage has higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifevantage$200.16M0.86$2.94M$0.6919.87
Grace TherapeuticsN/AN/A-$9.57M-$0.89-3.46

In the previous week, Lifevantage had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 4 mentions for Lifevantage and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.90 beat Lifevantage's score of 0.92 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Lifevantage Positive
Grace Therapeutics Very Positive

Summary

Lifevantage beats Grace Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRCE vs. The Competition

MetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$44.25M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-3.4621.1828.1020.05
Price / SalesN/A286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book0.638.378.665.87
Net Income-$9.57M-$55.19M$3.25B$258.55M
7 Day Performance-8.33%5.88%4.22%3.73%
1 Month Performance4.76%17.33%10.51%11.75%
1 Year PerformanceN/A4.42%34.40%18.03%

Grace Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRCE
Grace Therapeutics
2.5437 of 5 stars
$3.08
-3.8%
$12.00
+289.6%
N/A$44.25MN/A-3.46N/APositive News
LFVN
Lifevantage
4.2524 of 5 stars
$13.98
+0.9%
$30.50
+118.2%
+95.9%$176.01M$200.16M20.26260Positive News
IMAB
I-Mab
2.8665 of 5 stars
$2.12
+0.5%
$6.00
+183.0%
+51.8%$173.12M$3.89M0.00380
PBYI
Puma Biotechnology
4.2383 of 5 stars
$3.40
-1.4%
$7.00
+105.9%
-16.8%$168.74M$230.50M4.42200Upcoming Earnings
BIOA
BioAge Labs
N/A$4.70
-3.1%
N/AN/A$168.50MN/A0.00N/A
CCCC
C4 Therapeutics
2.8525 of 5 stars
$2.29
-5.4%
$12.00
+424.0%
-64.9%$162.61M$35.58M-1.56150Upcoming Earnings
NVCT
Nuvectis Pharma
2.5523 of 5 stars
$7.73
-1.7%
$17.00
+119.9%
+17.5%$161.48MN/A-6.848
ACOG
Alpha Cognition
1.7278 of 5 stars
$9.96
-0.3%
$20.00
+100.8%
N/A$159.56MN/A-8.30N/AGap Up
MOLN
Molecular Partners
2.5584 of 5 stars
$3.89
0.0%
$12.00
+208.6%
-31.5%$157.04M$5.65M-2.03180News Coverage
ENTA
Enanta Pharmaceuticals
4.0485 of 5 stars
$7.34
-5.0%
$18.00
+145.2%
-51.7%$156.93M$67.64M-1.62160News Coverage
LYEL
Lyell Immunopharma
2.5105 of 5 stars
$10.41
-5.3%
$15.00
+44.1%
-61.9%$154.17M$60K-0.42270News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:GRCE) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners